First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.
about
A Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerCurrent Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Targeted Therapies in Triple-Negative Breast CancerLiver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the LiteratureAntiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsAnti-vascular endothelial growth factor therapy in breast cancerTargeted Therapies for Brain Metastases from Breast CancerTriple-negative breast cancer: is there a treatment on the horizon?Cancer drug related cardiotoxicity during breast cancer treatment.Same Data; Different InterpretationsClinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trialsSorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.Standard of care and promising new agents for triple negative metastatic breast cancerG15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30.Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience.New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis.Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?Therapies for triple negative breast cancer.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Sorafenib for the treatment of breast cancer.Metastatic breast cancer: The Odyssey of personalization.Advancing Immunotherapy in Metastatic Breast Cancer.Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer.Antiangiogenic therapy in breast cancer.Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis.A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.
P2860
Q26752846-3CD53899-48E5-4EDB-8E94-3101A00CB222Q26764987-D1BDDE3A-9C56-49D7-9445-554EF0CB099AQ26775030-304ECAD6-4DB8-4398-821F-150D817B1555Q26777736-8274B0B8-BFF5-431F-92F9-424091C7E069Q26779880-6AF723D8-07B0-45A4-A315-5826532D31D1Q26822432-1647F13E-93BC-4212-93E9-8437EBF83C70Q26999473-3CDB7C33-BDFF-4A15-8B21-A0CC2DE71598Q28068154-8C2DFB3E-0F2D-4F96-97AF-DE7292D5C2B8Q28077243-9EFE0F1C-631E-4804-9607-A583C9B765A1Q30251498-948612C4-1D2A-482C-8747-3F83585702DEQ31125419-A4BB969B-3F51-4FB5-9042-81192087D9CBQ31157714-B2B75603-445E-4587-8B33-B4AE2BB73209Q33415281-01E1E25F-EBBE-4CD1-8200-B76AC19387C3Q33879154-E5D9BB29-BE90-4A25-8078-1D7A1E2D7928Q34042709-DEFB5143-461F-4209-9F36-1FBCC6B6C40CQ34658278-C1447625-6B4A-47D8-8502-A6F47F4DA032Q34774884-17A46DB7-9035-4AC0-A089-8D9937047CBAQ35826507-6A281EE4-70C7-405C-8E49-63AA65C80EF9Q36993476-53CC4742-0A2D-4EA3-A606-01CC0024D7D5Q37321051-9A685C44-E3A1-4227-B6FF-43C7AB6884F1Q38190433-1D8CD985-9616-4FCD-A0BB-C395F68899E1Q38322346-0E2105E5-C91F-4D97-8D60-38ACA8DAFD53Q38424397-1C2EE172-56D4-4381-9321-D5D1A3000A2FQ38550459-DC46AEFB-3028-4BF8-A6D0-CE6D56B87C26Q38641240-0011863C-51DD-4F6E-8CCC-6F12CDC80EBCQ38681598-90C013C8-987B-4808-88B8-01B8DE091F81Q38690276-3C6ED620-73EF-4970-9BDF-CCBA2C07FDA6Q38803271-7C5CF242-E757-4128-8C05-278E3661DF09Q38839151-C3DDA875-30EB-4394-AB30-17C0D481BAA2Q38852051-8CF8FFD8-A3F2-4635-A8B3-EAD546FC7EFAQ38881805-6DBA282D-CF88-4257-8852-C535B378A15AQ38901163-43515059-491E-4B26-84B5-6BCCDB93FE6EQ39324161-579FC209-5366-48D7-8F40-B9D5E141A819Q39933767-421BF04D-35BD-4B4C-AEB6-0014C88C27CCQ39967942-70F7108D-8B14-4D24-AC83-14AB83B4B996Q41742917-4A5DCCC2-9D40-4209-9B09-C168CF3F7A4AQ42480116-EA575EE7-FE1F-487A-884A-59CD4EF011D7Q47111400-8A4BAB40-1B6C-49BC-8384-AE47544192ECQ48230021-A730548F-88F5-4892-8D7D-C2418823F5BDQ51319007-FD2C41A1-2C4F-44E2-ACA5-D69670325C93
P2860
First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
First-line bevacizumab in comb ...... es of data from 2447 patients.
@ast
First-line bevacizumab in comb ...... es of data from 2447 patients.
@en
type
label
First-line bevacizumab in comb ...... es of data from 2447 patients.
@ast
First-line bevacizumab in comb ...... es of data from 2447 patients.
@en
prefLabel
First-line bevacizumab in comb ...... es of data from 2447 patients.
@ast
First-line bevacizumab in comb ...... es of data from 2447 patients.
@en
P2093
P2860
P356
P1433
P1476
First-line bevacizumab in comb ...... ses of data from 2447 patients
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDT276
P577
2013-07-25T00:00:00Z